| Not Yet Recruiting | Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastat NCT07183852 | Vastra Gotaland Region | Phase 1 |
| Recruiting | Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma NCT07276386 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Recruiting | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma NCT07136181 | Novelwise Pharmaceutical Corporation | Phase 1 / Phase 2 |
| Recruiting | Tebentafusp-tebn With LDT in Metastatic UM NCT06626516 | Thomas Jefferson University | Phase 1 / Phase 2 |
| Recruiting | Adding IL-2 to Tebentafusp to Eradicate Cancer Progression NCT07063875 | St Vincent's Hospital, Sydney | Phase 1 / Phase 2 |
| Recruiting | Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma NCT06627244 | University of Miami | Phase 2 |
| Recruiting | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in I NCT06581406 | Replimune, Inc. | Phase 2 / Phase 3 |
| Recruiting | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma NCT06121180 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma NCT05987332 | IDEAYA Biosciences | Phase 2 / Phase 3 |
| Completed | Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Met NCT04812470 | Vastra Gotaland Region | Phase 1 |
| Withdrawn | Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanc NCT05677373 | Alliance for Clinical Trials in Oncology | Phase 1 / Phase 2 |
| Recruiting | A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or D NCT05607095 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLU NCT05282901 | Institut Curie | Phase 2 |
| Active Not Recruiting | A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas NCT05415072 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Unknown | An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Do NCT05022901 | Delcath Systems Inc. | Phase 3 |
| Active Not Recruiting | Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma NCT05170334 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide NCT05075993 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases NCT04728633 | Thomas Jefferson University | Phase 2 |
| Terminated | FHD-286 in Subjects With Metastatic Uveal Melanoma NCT04879017 | Foghorn Therapeutics Inc. | Phase 1 |
| Completed | Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTO NCT04118062 | Institut Curie | N/A |
| Terminated | Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma NCT04720417 | Thomas Jefferson University | Phase 2 |
| Completed | Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma NCT04552223 | Jose Lutzky, MD | Phase 2 |
| Recruiting | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions NCT03947385 | IDEAYA Biosciences | Phase 1 / Phase 2 |
| Terminated | Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma NCT03865212 | Mayo Clinic | Phase 1 |
| Recruiting | Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease NCT03025256 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in th NCT03472586 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye NCT02697630 | Vastra Gotaland Region | Phase 2 |
| Unknown | Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating NCT03068624 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Me NCT02831933 | Eric Bernicker, MD | Phase 2 |
| Terminated | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma NCT01814046 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma NCT01585194 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Vorinostat in Treating Patients With Metastatic Melanoma of the Eye NCT01587352 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma NCT01328106 | GlaxoSmithKline | Phase 2 |
| Completed | A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma NCT01551459 | The Clatterbridge Cancer Centre NHS Foundation Trust | Phase 2 |
| Unknown | A Study to Assess PV-10 Chemoablation of Cancer of the Liver NCT00986661 | Provectus Biopharmaceuticals, Inc. | Phase 1 |